重大事件
即時報告
8-K
2026-06-17
戴纳基提交8-K 报告，披露签订重大最终协议及产生
AI 繁中摘要
Dyne Therapeutics（代碼：DYN）於2026年6月17日向美國證監會提交8-K即時報告，報告日期為2026年6月16日。本次申報主要涉及兩項事項：Item 1.01「簽訂重大最終協議」及Item 2.03「產生直接財務義務或表外安排義務」。公司未在摘要中披露協議具體條款，但暗示可能通過融資或債務工具取得資金，或涉及合作/授權協議。投資者應密切關注後續完整披露，以評估對公司財務狀況及股本結構的潛在影響。該公司為生物製藥企業，專注於肌肉疾病療法開發。
展開英文正文
EDGAR Filing Documents for 0001818794-26-000003 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001818794-26-000003 Filing Date 2026-06-17 Accepted 2026-06-17 07:35:15 Documents 9 Period of Report 2026-06-16 Items Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Interactive Data Document Format Files Seq Description Document Type Size 1 8-K dyn-20260616.htm iXBRL 8-K 60048 Complete submission text file 0001818794-26-000003.txt 173047 Data Files Seq Description Document Type Size 2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dyn-20260616.xsd EX-101.SCH 30687 12 EXTRACTED XBRL INSTANCE DOCUMENT dyn-20260616_htm.xml XML 4519 Mailing Address 1560 TRAPELO ROAD WALTHAM MA 02451 Business Address 1560 TRAPELO ROAD WALTHAM MA 02451 (781) 786-8230 Dyne Therapeutics, Inc. (Filer) CIK: 0001818794 (see all company filings) EIN.: 364883909 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-39509 | Film No.: 261096600 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)